BCL2 and prostate carcinoma: The higher levels of bcl-2 immunostaining generally seen here in association with more advanced Gleason grade and metastatic disease suggest that an increase in the ratio of these anti-apoptotic proteins often occurs during progression of prostate cancers.1 The intensity of bcl-2 immunostaining and the percentage of immunopositive cells are generally higher in the more advanced tumors, largely accounting for the higher composite scores.1